PHASE I STUDY OF MONOCLONAL ANTIBODY FRAGMENT 131I MEL-14 F(AB')2 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT MELANOMA AND OTHER BRAIN TUMORS

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed primary or metastatic malignant melanoma
OR Histologically confirmed supratentorial malignant brain tumor Newly diagnosed or
recurrent primary or metastatic tumor Eligible primary histologies, including but not
limited to: Glioblastoma multiforme Mixed anaplastic glioma Anaplastic astrocytoma Other
astrocytoma Gliosarcoma Anaplastic oligodendroglioma The following excluded: Diffusely
infiltrating tumors Multifocal tumors Infratentorial tumors Subependymal spread No
measurable enhancing lesion extending more than 1 cm beyond margins of surgical cavity on
contrast-enhanced CT or MRI performed within 72 hours after resection Intralesional
catheter placed at resection Patency of catheter demonstrated by radiolabeled albumin flow
Reactivity of neoplastic cells with intact Me1-14 IgG2a or Me1-14 F(ab')2 demonstrated by
immunohistology with polyclonal rabbit antibody or monoclonal mouse antibody

PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50%-100%
Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater
than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 1.5 times normal
Alkaline phosphatase less than 1.5 times normal Renal: Creatinine less than 1.2 mg/dL
Other: Not pregnant

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks
since antineoplastic chemotherapy unless unequivocal tumor progression Endocrine therapy:
Concurrent corticosteroids allowed at lowest possible dose and stable for at least 10 days
prior to entry Radiotherapy: At least 3 months since radiotherapy to site of measurable
disease within the nervous system unless unequivocal tumor progression Surgery: See
Disease Characteristics